Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

26.05.26 23:45 Uhr

Werte in diesem Artikel
Aktien

72,00 EUR 0,30 EUR 0,42%

11,70 EUR 0,70 EUR 6,36%

Indizes

PKT PKT

19.450,9 PKT 249,2 PKT 1,30%

3.701,0 PKT 29,5 PKT 0,80%

7.534,7 PKT 51,5 PKT 0,69%

Medtronic (MDT) closed at $77.60 in the latest trading session, marking a -1.27% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.61%. Meanwhile, the Dow experienced a drop of 0.23%, and the technology-dominated Nasdaq saw an increase of 1.19%. Heading into today, shares of the medical device company had lost 5.21% over the past month, lagging the Medical sector's gain of 2.73% and the S&P 500's gain of 4.44%.Investors will be eagerly watching for the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on June 3, 2026. It is anticipated that the company will report an EPS of $1.56, marking a 3.7% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $9.66 billion, indicating a 8.26% increase compared to the same quarter of the previous year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.55 per share and a revenue of $36.18 billion, signifying shifts of +1.09% and +7.89%, respectively, from the last year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medtronic. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.14% lower. Currently, Medtronic is carrying a Zacks Rank of #4 (Sell). Looking at its valuation, Medtronic is holding a Forward P/E ratio of 12.94. This valuation marks a discount compared to its industry average Forward P/E of 18.7. One should further note that MDT currently holds a PEG ratio of 1.87. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 1.48 based on yesterday's closing prices. The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 169, placing it within the bottom 31% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Quelle: Zacks

Nachrichten zu Medtronic PLC

Analysen zu Medtronic PLC

DatumRatingAnalyst
04.02.2019Medtronic Strong BuyNeedham & Company, LLC
03.01.2019Medtronic BuyDeutsche Bank AG
16.10.2018Medtronic OverweightBarclays Capital
22.08.2018Medtronic HoldStifel, Nicolaus & Co., Inc.
13.08.2018Medtronic Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
04.02.2019Medtronic Strong BuyNeedham & Company, LLC
03.01.2019Medtronic BuyDeutsche Bank AG
16.10.2018Medtronic OverweightBarclays Capital
22.08.2018Medtronic HoldStifel, Nicolaus & Co., Inc.
13.08.2018Medtronic Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
01.06.2016Medtronic NeutralWedbush Morgan Securities Inc.
23.11.2012Medtronic holdDeutsche Bank Securities
22.11.2012Medtronic neutralCredit Suisse Group
22.11.2012Medtronic neutralJP Morgan Chase & Co.
21.11.2012Medtronic sector performRBC Capital Markets
DatumRatingAnalyst
22.08.2007Medtronic underweightMorgan Stanley
29.09.2006Update Kyphon Inc.: UnderweightMorgan Stanley

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Medtronic PLC nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen